Asston Pharmaceuticals
- Market cap
- ₹ 111 Cr.
- P/E
- 40.8x
- P/B
- 2.71x
- 52-week range
- 60 – 148
- ROE
- 16%
- ROCE
- 17%
- Dividend yield
- 0%
- Debt / equity
- 0.13
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE SME
About
Asston Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The Company is engaged in the business of manufacturing and marketing tablets, capsules, oral liquid, external preparations (ointment, cream, gel and lotion), and oral powder (sachet, dry syrup), and others. It also manufactures various pharmaceutical products for different marketers on a loan license or on a contract manufacturing basis. Its business is primarily conducted on a principle-to-principal basis with various marketers. It operates in supplying pharmaceutical products directly to distributors and pharmacies. Its tablets include Aceclofenac Tablets BP 100 mg; Albendazole Tablets USP 400 mg; B-complex Tablets, and more. Its capsules include Amoxicillin Capsules BP 250 / 500 mg; Ampicillin and Cloxacillin Capsules 500 mg; Ampicillin Capsules BP 250 / 500 mg, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Asston Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)40.8 against a typical 34.3: pricier than most peers (1st = cheapest).133rd of 220
- Share price, 3 months+128% against a typical −0.5%.2nd of 200
- Size₹ 110.8 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).145th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 16 | 9 | 15 | 10 |
| Expenses | 14 | 6 | 13 | 13 |
| Operating Profit | 2 | 3 | 2 | −3 |
| OPM % | 14.2% | 35.1% | 14.5% | −27.9% |
| Other Income | 1 | −0 | −2 | 5 |
| Interest | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 0 | 1 |
| Tax % | 22.8% | 23.4% | −50% | 59.8% |
| Net Profit | 2 | 2 | 0 | 0 |
| EPS in Rs | 24.24 | 3.11 | 0.04 | 0.56 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 57%
- TTM
- 2%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 55%
- TTM
- 4%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 28%
- 3 Years
- 26%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Asston Pharmaceuticals | ₹ 148.00 | ₹ 111 Cr. | 40.8x | 2.7x | 16% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 34.7x | 5x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 91.3x | 14.3x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 69.9x | 18.5x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.8x | 4.2x | — | 15.7% |
| Laurus Labs | ₹ 1,974.00 | ₹ 1,06,658 Cr. | 123.1x | 20.8x | — | 15% |
Management
- Saili Jayaram More
- Whole Time Director, Chief Executive Officer
- Sumit Pawar
- Chief Financial Officer
- Rishi Upadhaya
- Compliance Officer, Company Secretary
- Ashish Narayan Sakalkar
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.